Clinical Trials Logo
  1. Home
  2. Wiskott-Aldrich Syndrome
  3. NCT04350164

Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.

Wiskott-Aldrich Syndrome Clinical Trial

Official title:
Retrospective Chart Review of Children With Wiskott-Aldrich Syndrome Who Received Romiplostim in Treatment of Thrombocytopenia.

Clinical Trial Summary

The rationale for this retrospective study is to evaluate the efficacy and safety of thrombopoietin-receptor agonist (TPO-RA) romiplostim for reducing thrombocytopenia and bleeding tendency in pediatric participants with genetically confirmed Wiskott-Aldrich syndrome (WAS).

Clinical Trial Description

Thrombocytopenia is a life-threatening symptom in WAS patients. Subjects with WAS are at increased risk of debilitating and\ or life-threatening bleedings due to low platelet numbers. Hematopoietic stem cell transplantation is an effective treatment of WAS and all its symptoms yet requires time for donor search and is not widely utilized in cases with mild WAS with isolated thrombocytopenia. TPO-RAs have been used in individual WAS patients, wherein publications describing large WAS cohorts treated with TPO-RAs are lacking. Based on the previous reports, WAS patients in our Center have been receiving treatment with TPO-RA romiplostim since 2012. The aim of the study is to retrospective analyze patients' data in order to asses treatment efficacy and safety of romiplostim in WAS thrombocytopenia. The study will collect and analyze information that is already in the patients' medical records. Information about clinical data (assessment of bleeding tendency with a modified World Health Organization (WHO) Bleeding Scale), laboratory values (such as clinical and biochemical analysis of blood) will be included. Evaluation of the efficacy therapy was based on the results of physical examination, including bleeding events at the time of diagnosis and after 6-month TPO-RA was initiated and platelet response. A complete response was defined as a platelet count >100 x 109/L in the absence of bleeding symptoms, partial - 30 x 109/L higher than the patient's pretreatment baseline count to 100 x 109/L. Non-response was defined as not achieving a platelet count of > 30 x 109/L from the baseline count. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04350164
Study type Observational
Source Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Contact
Status Completed
Phase
Start date April 1, 2012
Completion date June 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01652092 - Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies N/A
Completed NCT01953016 - Participation in a Research Registry for Immune Disorders
Active, not recruiting NCT02333760 - Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome Phase 1/Phase 2
Terminated NCT01319851 - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Recruiting NCT04371939 - Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome Phase 2
Completed NCT01347346 - Gene Therapy for WAS Phase 1/Phase 2
Completed NCT00160355 - Haploidentical Hematopoietic Stem Cell Transplantation Patients With Wiskott-Aldrich Syndrome Phase 1
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT01289847 - A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Phase 4
Completed NCT01347242 - Gene Therapy for Wiskott-Aldrich Syndrome (WAS) Phase 1/Phase 2
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Enrolling by invitation NCT03198195 - Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome N/A
Recruiting NCT03019809 - A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Phase 2
Terminated NCT00909363 - Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients Phase 2
Enrolling by invitation NCT01852370 - Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Phase 1/Phase 2
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Active, not recruiting NCT01410825 - Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome Phase 1/Phase 2
Active, not recruiting NCT00004341 - Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders N/A
Completed NCT03399461 - Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)